Table 1 Patient demographics and disease characteristics of the Asian subgroup and the global OlympiAD study population.
Asian subgroup | Global OlympiAD study population | |||
|---|---|---|---|---|
Olaparib (N = 59) | Chemotherapy TPC (N = 28) | Olaparib (N = 205) | Chemotherapy TPC (N = 97) | |
Median age, years (range) | 46.0 (28–74) | 47.0 (24–66) | 44.0 (22–76) | 45.0 (24–68) |
Median body weight, kg (range) | 59.0 (36–85) | 55.5 (39–86) | 64.0 (36–113) | 62.0 (39–112) |
Male, n (%) | 1 (1.7) | 1 (3.6) | 5 (2.4) | 2 (2.1) |
ECOG performance status, n (%) | ||||
0 1 | 42 (71.2) 17 (28.8) | 20 (71.4) 8 (28.6) | 148 (72.2) 57 (27.8) | 62 (63.9) 35 (36.1) |
BRCAm status, n (%)* | ||||
BRCA1 BRCA2 Both Missing | 30 (52.8) 25 (42.4) 3 (5.1) 1 (1.7) | 12 (42.9) 16 (57.1) 0 0 | 117 (57.1) 84 (41.0) 4 (2.0) 0 | 51 (52.6) 46 (47.4) 0 0 |
Hormone receptor status, n (%) | ||||
ER+ and/or PR+ TNBC | 29 (49.2) 30 (50.8) | 13 (46.4) 15 (53.6) | 103 (50.2) 102 (49.8) | 49 (50.5) 48 (49.5) |
Prior chemotherapy for mBC, n (%) | 41 (69.5) | 23 (82.1) | 146 (71.2) | 69 (71.1) |
Prior platinum treatment, n (%) | 21 (35.6) | 8 (28.6) | 60 (29.3) | 26 (26.8) |
Chemotherapy TPC, n (%)† | NA | NA | ||
Capecitabine Vinorelbine Eribulin | 10 (35.7) 5 (17.9) 12 (42.9) | 41 (42.3) 16 (16.5) 34 (35.1) | ||
